comparemela.com

Latest Breaking News On - Trial under preparation - Page 1 : comparemela.com

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update

Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial expected in early December 2023Patients who completed the 18-month PARADIGM trial, including the.

United kingdomPrnewswire neurosense therapeutics ltdCompany phaseDrug administrationExchange commissionEuropean medicines agency neurosense opens eu officeEuropean medicines agencyNeurosense therapeutics ltdSense therapeuticsAmyotrophic lateral sclerosisCompleted double blind segmentInvestigator initiated trialSlow vital capacityPrimec aheadPivotal phaseSponsored study demonstrated primec

NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United statesUnited kingdomGhazaleh sadri vakiliHospital neuroepigenetics labNeurosense therapeutics ltdPrnewswire neurosense therapeutics ltdSense therapeuticsPatient enrollmentParticipants who completedTrial choseTrial under preparationMassachusetts general hospitalNeuroepigenetics labImprove early detectionInterim unaudited consolidated statements

vimarsana © 2020. All Rights Reserved.